Aspire Biopharma went public via a SPAC merger with PowerUp Acquisition in a $316m deal.

Aspire Biopharma, a developer of a multi-faceted patent protected disruptive drug delivery mechanism technology, went public via a SPAC merger with PowerUp Acquisition, a special purpose acquisition company, in a $316m deal. “We have several significant initiatives on the horizon, and we are truly looking forward to working with Suren Ajjarapu and his team as the combined company is set to deliver Aspire’s innovative, patent-pending technology to a large addressable market. As we step into this next phase of our growth, I'm incredibly proud of what our team has accomplished over the past year in building a strong foundation. With an innovative product tailored to address many of the shortcomings of existing drug and nutraceutical formulations, Aspire is ready for the next big leap. Our partnership with the PowerUp team will help us share our product vision with the world and pave the way for the launch of our first product, Instaprin," Kraig Higginson, Aspire CEO.